← Barinthus Biotherapeutics plc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Net Income From Continuing Operations | ($17.9m) | ($51.1m) | $5.3m | ($73.4m) | ($61.2m) | ($66.5m) | ($41.8m) | |
| Net loss | ($17.9m) | ($51.1m) | $5.3m | ($73.4m) | ($61.2m) | ($66.5m) | — | |
| Net Income (Loss) Attributable to Parent | ($17.7m) |
($50.9m)
-187.28%
|
$5.3m
+110.50%
|
($73.3m)
-1473.03%
|
($61.1m)
+16.73%
|
($66.4m)
-8.77%
|
— | |
| Net Income (Loss) Attributable to Noncontrolling Interest | ($227k) | ($247k) | ($21k) | ($100k) | ($109k) | ($30k) | — | |
| Depreciation, Depletion and Amortization | $208k | $602k | $4.3m | $5.4m | $5.8m | $5.8m | $3.5m | |
| Depreciation | $208k | $420k | $1.1m | $2.3m | $2.6m | $2.9m | $3.5m | |
| Amortization of Intangible Assets | $0 | $182k | $3.2m | $3.2m | $3.2m | $3.0m | — | |
| Depreciation Amortization Depletion | — | — | $4.3m | $5.4m | $5.8m | $5.8m | $3.5m | |
| Deferred Income Tax Expense (Benefit) | — | ($119k) | ($4.3m) | ($3.1m) | ($44k) | ($175k) | ($167k) | |
| Deferred tax benefit | — | ($119k) | ($4.3m) | ($3.1m) | ($44k) | ($175k) | — | |
| Share-based Payment Arrangement, Noncash Expense | $3.6m | $16.5m | $9.9m | $5.1m | $4.7m | $468k | $1.3m | |
| Share-based Payment Arrangement, Expense | $3.6m | $16.5m | $9.9m | $5.1m | $4.7m | $468k | $1.3m | |
| Goodwill, Impairment Loss | — | — | $0 | $0 | $12.2m | $0 | $5.8m | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | $0 | $4.7m | — | |
| Operating Lease, Impairment Loss | — | — | — | — | $2.6m | $400k | — | |
| Impairment of long-lived assets | — | — | — | $0 | $5.3m | $5.8m | — | |
| Impairment of goodwill | — | — | — | $0 | $12.2m | $0 | — | |
| Asset Impairment Charge | — | — | — | $0 | $17.5m | $5.8m | $5.8m | |
| Other Nonoperating Income (Expense) | $42k | $332k | $567k | $1.1m | $135k | $16k | — | |
| Nonoperating Income (Expense) | $2.2m | ($5.9m) | $4.9m | $7.4m | $6.7m | $3.9m | — | |
| Changes in operating assets and liabilities: | ||||||||
| Change In Working Capital | — | — | ($5.5m) | $6.2m | $2.6m | ($359k) | $4.8m | |
| Increase (Decrease) in Accounts Receivable | ($479k) | ($559k) | $5.8m | ($5.8m) | $0 | — | $3.1m | |
| Change In Receivables | — | — | ($4.7m) | $5.7m | ($2.3m) | $6.4m | $3.1m | |
| Changes In Account Receivables | — | $559k | ($5.8m) | $5.8m | $0 | — | $3.1m | |
| Increase (Decrease) in Accounts Payable | $586k | ($3.5m) | $1.1m | ($3.4m) | $898k | ($2.2m) | ($1.2m) | |
| Change In Payables And Accrued Expense | — | — | $1.9m | ($1.4m) | $1.4m | ($6.0m) | ($1.2m) | |
| Accrued expenses and other current liabilities | $1.0m | $4.4m | $751k | $2.0m | $456k | ($3.8m) | — | |
| Change In Accrued Expense | — | — | $751k | $2.0m | $456k | ($3.8m) | $1.7m | |
| Prepaid expenses and other current assets | ($435k) | ($4.2m) | ($2.2m) | $2.2m | $3.6m | $1.7m | — | |
| Change In Other Current Assets | — | ($735k) | ($387k) | $128k | $0 | — | $0 | |
| Change In Other Current Liabilities | — | — | $0 | ($445k) | ($1.8m) | ($2.0m) | ($2.3m) | |
| Net Cash Provided by (Used in) Operating Activities | ($11.0m) |
($32.6m)
-195.46%
|
($14.4m)
+55.71%
|
($50.9m)
-252.89%
|
($28.9m)
+43.17%
|
($48.0m)
-65.79%
|
($26.4m)
+44.92%
|
|
| Cash flows from investing activities: | ||||||||
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | $348k | $0 | $0 | $245k | ($2.4m) | |
| Payments to Acquire Property, Plant, and Equipment | $293k | $1.1m | $6.1m | $5.4m | $892k | $37k | ($37k) | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | $11.8m | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($293k) | ($12.9m) | ($5.8m) | ($5.4m) | ($892k) | $416k | $569k | |
| Cash flows from financing activities: | ||||||||
| Gain (Loss) on Extinguishment of Debt | — | ($13.8m) | — | — | — | — | — | |
| Net Issuance Payments Of Debt | — | $0 | ($159k) | $0 | — | — | — | |
| Net Long Term Debt Issuance | — | $0 | ($159k) | $0 | — | — | — | |
| Net Short Term Debt Issuance | — | $0 | ($159k) | — | — | — | — | |
| Long Term Debt Payments | — | $0 | ($159k) | $0 | — | — | — | |
| Repayment Of Debt | — | $0 | ($159k) | $0 | — | — | — | |
| Short Term Debt Payments | — | $0 | ($159k) | — | — | — | — | |
| Issuance Of Capital Stock | — | — | $484k | $2.0m | $2.2m | $0 | $0 | |
| Proceeds from Issuance of Common Stock | — | $102.8m | $484k | $2.0m | $2.2m | $0 | $0 | |
| Common Stock Issuance | — | — | $484k | $2.0m | $2.2m | $0 | $0 | |
| Net Other Financing Charges | — | ($5.3m) | — | ($163k) | — | — | — | |
| Net Cash Provided by (Used in) Financing Activities | $41.4m |
$222.7m
+437.57%
|
$325k
-99.85%
|
$1.9m
+476.00%
|
$2.2m
+15.54%
|
$2k
-99.91%
|
$0
-100.00%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $31.8m | $170.8m | ($19.7m) | ($52.3m) | ($29.7m) | ($40.5m) | $61.9m | |
| Beginning Cash Position | — | — | $214.1m | $194.4m | $142.1m | $112.4m | $87.8m | |
| Cash, cash equivalents and restricted cash, beginning of the period | $43.3m | $214.1m | $194.4m | $142.1m | $112.4m | $71.9m | — | |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $1.7m | ($6.5m) | $187k | $2.2m | ($2.0m) | $7.0m | — | |
| Net decrease in cash, cash equivalents and restricted cash | $31.8m | $170.8m | ($19.7m) | ($52.3m) | ($29.7m) | ($40.5m) | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $43.3m | $214.1m | $194.4m | $142.1m | $112.4m | $71.9m | $61.9m | |
| Effect Of Exchange Rate Changes | — | — | $187k | $2.2m | ($2.0m) | $7.0m | ($2.3m) | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Income Tax Expense (Benefit) | $95k | ($28k) | ($4.5m) | ($3.1m) | ($44k) | ($175k) | — | |
| Interest Expense Nonoperating | — | — | — | — | $53k | $51k | — | |
| Non-cash interest expense | — | — | $19k | $28k | $48k | $51k | — | |
| Operating lease liabilities | — | — | $0 | ($445k) | ($1.8m) | ($2.0m) | — | |
| Additional Financial Items | ||||||||
| Foreign Currency Transaction Gain (Loss), before Tax | $462k | $325k | $26.4m | ($7.6m) | $2.4m | ($9.6m) | — | |
| Foreign Currency Transaction Gain (Loss), Unrealized | $448k | $209k | $24.9m | ($7.5m) | $649k | ($3.7m) | — | |
| General and Administrative Expense | $10.5m | $25.1m | $6.4m | $39.8m | $29.7m | $40.8m | — | |
| Goodwill | — | $12.6m | $12.2m | $12.2m | $0 | — | $5.8m | |
| Investment Income, Interest | $0 | $2k | $3.1m | $2.9m | $2.7m | $2.0m | — | |
| Operating Expenses | $24.9m | $45.5m | $48.7m | $84.7m | $84.1m | $71.1m | — | |
| Share based compensation | $3.6m | $16.5m | $9.9m | $5.1m | $4.7m | $468k | $1.3m | |
| Non-cash lease expenses | — | $338k | $1.2m | $1.3m | $1.4m | $3.3m | — | |
| Unrealized foreign exchange loss | ($448k) | ($209k) | ($24.9m) | $7.5m | ($649k) | $3.7m | — | |
| Change in contingent consideration | — | — | ($73k) | $55k | $866k | $26k | — | |
| Research and development incentives receivable | $295k | ($3.6m) | $1.2m | ($127k) | ($2.3m) | $6.4m | — | |
| Deferred income | — | — | — | $0 | $1.7m | ($506k) | ($167k) | |
| Issue of shares from the exercise of stock options | — | $9k | $0 | $0 | $0 | $2k | — | |
| Proceeds from issue of ordinary shares, net of issuance costs | — | $102.8m | $484k | $2.0m | $2.2m | $0 | — | |
| Cash Flow From Continuing Financing Activities | — | — | $325k | $1.9m | $2.2m | $2k | $0 | |
| Cash Flow From Continuing Investing Activities | — | — | ($5.8m) | ($5.4m) | ($892k) | $416k | $569k | |
| Change In Account Payable | — | — | $1.1m | ($3.4m) | $898k | ($2.2m) | ($1.2m) | |
| Change In Other Working Capital | — | ($63k) | ($183k) | — | $1.7m | ($506k) | ($1.2m) | |
| Change In Payable | — | — | $1.1m | ($3.4m) | $898k | ($2.2m) | ($1.2m) | |
| Change In Prepaid Assets | — | — | ($2.2m) | $2.2m | $3.6m | $1.7m | $4.7m | |
| Changes In Cash | — | — | ($19.9m) | ($54.5m) | ($27.7m) | ($47.6m) | ($25.9m) | |
| End Cash Position | — | — | $194.4m | $142.1m | $112.4m | $71.9m | $61.9m | |
| Financing Cash Flow | — | — | $325k |
$1.9m
+476.00%
|
$2.2m
+15.54%
|
$2k
-99.91%
|
$0
-100.00%
|
|
| Free Cash Flow | — | — | ($20.6m) | ($56.3m) | ($29.8m) | ($48.0m) | ($26.4m) | |
| Gain Loss On Sale Of PPE | — | — | ($348k) | $0 | $0 | ($245k) | ($34k) | |
| Investing Cash Flow | — | — | ($5.8m) | ($5.4m) | ($892k) | $416k | $569k | |
| Net Business Purchase And Sale | — | ($11.8m) | $0 | — | — | — | — | |
| Net Foreign Currency Exchange Gain Loss | — | — | ($24.9m) | $7.5m | ($649k) | $3.7m | ($2.4m) | |
| Net PPE Purchase And Sale | — | — | ($5.8m) | ($5.4m) | ($892k) | $416k | $569k | |
| Net Preferred Stock Issuance | — | $125.2m | $0 | — | — | — | — | |
| Operating Gains Losses | — | — | ($25.3m) | $7.5m | ($649k) | $3.5m | ($2.4m) | |
| Other Non Cash Items | — | — | $1.2m | $1.4m | $2.4m | $3.4m | — | |
| Proceeds From Stock Option Exercised | — | — | $0 | $0 | $0 | $2k | $0 | |
| Purchase Of Business | — | ($11.8m) | $0 | — | — | — | — | |
| Purchase Of PPE | — | — | ($6.1m) | ($5.4m) | ($892k) | ($37k) | ($37k) | |
| Sale Of PPE | — | — | $388k | $0 | $0 | $453k | $569k | |
| Stock Based Compensation | — | — | $9.9m | $5.1m | $4.7m | $468k | $1.3m | |
| Supplemental disclosure of cash flow information: | ||||||||
| Change In Cash Supplemental As Reported | — | — | ($19.7m) | ($52.3m) | ($29.7m) | ($40.5m) | — | |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $2k | $1.8m | $0 | $0 | — | — | — | |
| Income Taxes Paid, Net | — | $152k | $0 | $0 | — | — | — |